Vidar Beisvåg

1.6k citations
38 papers · 757 indexed · h-index 17
Topics
Renal cell carcinoma treatment (7 papers)Renal and related cancers (5 papers)Helicobacter pylori-related gastroenterology studies (5 papers)

In The Last Decade

Vidar Beisvåg

37 papers receiving 747 citations

Peers

Vidar Beisvåg
Comparison fields: 5 of 100
  • Molecular Biology 371
  • Genetics 142
  • Cardiology and Cardiovascular Medicine 122
  • Cancer Research 120
  • Surgery 108
Replace Jaap van Doorn with:
Jaap van Doorn Netherlands
Serena Vitale Italy
Martin Mollenhauer Germany
Makoto Kubo Japan
Jacqueline Brassard United States
Hongwen Zhang China
Stacy L. Musone United States
Cem Sezer Türkiye
Ben Rhoades United States
Vidar Beisvåg relative to Jaap van Doorn Netherlands Jaap van Doorn's profile →
Citations per field
00.5×1.5×2.2×
Jaap van Doorn · 1×
Citations per year

Countries citing papers authored by Vidar Beisvåg

Since Specialization
Citations

This map shows the geographic impact of Vidar Beisvåg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vidar Beisvåg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vidar Beisvåg more than expected).

Fields of papers citing papers by Vidar Beisvåg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vidar Beisvåg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vidar Beisvåg. The network helps show where Vidar Beisvåg may publish in the future.

Co-authorship network of co-authors of Vidar Beisvåg

This figure shows the co-authorship network connecting the top 25 collaborators of Vidar Beisvåg. A scholar is included among the top collaborators of Vidar Beisvåg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vidar Beisvåg. Vidar Beisvåg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 3
2 15
3 17
4 6
5 9
6 3
7 41
8 5
9 17
10 47
11 6
12 19
13 91
14 9
15 5
16 3
17 19
18 79
19 2
20 25

About Vidar Beisvåg

Vidar Beisvåg is a scholar working on Cancer Research, Molecular Biology and Transplantation, having authored 38 papers that have together received 757 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (7 papers), Renal and related cancers (5 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). The work is most often cited by research in Cancer Research (120 citations), Gastroenterology (43 citations) and Molecular Biology (371 citations). Vidar Beisvåg has collaborated with scholars based in Norway, United States and Finland. Frequent co-authors include Arne K. Sandvik, Arnar Flatberg, Øyvind Ellingsen, Jan Pål Loennechen, Atle van Beelen Granlund, Helge L. Waldum, Ulrik Wisløff, Ann Elisabet Østvik, Sverre H. Torp and Mette Langaas. Their work appears in journals such as Blood, PLoS ONE and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026